The Impact of Receptor Binding Avidity and Immune History on the Antigenic Determination of Influenza A Viruses by Li, Yang
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
1-1-2013
The Impact of Receptor Binding Avidity and
Immune History on the Antigenic Determination
of Influenza A Viruses
Yang Li
University of Pennsylvania, yangli1@mail.med.upenn.edu
Follow this and additional works at: http://repository.upenn.edu/edissertations
Part of the Allergy and Immunology Commons, Immunology and Infectious Disease Commons,
Medical Immunology Commons, and the Virology Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/edissertations/888
For more information, please contact libraryrepository@pobox.upenn.edu.
Recommended Citation
Li, Yang, "The Impact of Receptor Binding Avidity and Immune History on the Antigenic Determination of Influenza A Viruses"
(2013). Publicly Accessible Penn Dissertations. 888.
http://repository.upenn.edu/edissertations/888
The Impact of Receptor Binding Avidity and Immune History on the
Antigenic Determination of Influenza A Viruses
Abstract
Most humans are repeatedly infected with new strains of influenza throughout their lifetime even though
protective neutralizing antibodies against the viral hemagglutinin (HA) are generated after both natural
infection and vaccination. This observed lack of protection against variant strains is largely attributed to a
process termed `antigenic drift', where accumulating mutations in HA quickly abrogate recognition by
antibodies elicited by earlier strains. Consequently, current influenza vaccines must be updated frequently in
an attempt to match the antigenic profiles of vaccine strains to those of circulating strains. However, the
existing process of antigenic determination is imperfect: it fails to consider the effects of receptor binding
avidity in the interpretation of hemagglutination inhibition (HAI) assays or the effects of pre-exposure history
on how a novel virus is viewed antigenically by an altered immune system. Here, we designed a series of
experiments to address these issues. First, we computationally modeled how variation in receptor binding
avidity could affect the antigenic characterization of historic H3N2 strains and experimentally demonstrated
that single point mutations in HA can skew HAI titers without actually affecting antibody binding.
Additionally, using the same H3N2 system, we showed that a single amino acid mutation can significantly
alter the immunodominance of the anti-HA antibody response. We then completed a series of studies to
determine how immune history influences the specificity of antibody repertoires. In examining patient
serology, we found that the specificity of the human antibody response against the 2009 pandemic H1N1
virus (pH1N1) was highly correlated with pre-exposure history to different seasonal H1N1 (sH1N1) strains
during childhood. Using a ferret model, we demonstrate that the anti-pH1N1 antibody response can be
shifted to highly conserved epitopes on HA when the animals were primed with sH1N1s that are otherwise
antigenically distinct. Collectively, our studies demonstrate that accounting for receptor binding avidity and
factors that alter antibody repertoires will improve influenza vaccination strategies in the future.
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ABSTRACT 
THE IMPACT OF RECEPTOR BINDING AVIDITY AND IMMUNE HISTORY ON THE 
ANTIGENIC DETERMINATION OF INFLUENZA A VIRUSES 
Yang Li 
Scott E.  Hensley 
Most humans are repeatedly infected with new strains of influenza throughout their 
lifetime even though protective neutralizing antibodies against the viral hemagglutinin (HA) are 
generated after both natural infection and vaccination.  This observed lack of protection against 
variant strains is largely attributed to a process termed ‘antigenic drift’, where accumulating 
mutations in HA quickly abrogate recognition by antibodies elicited by earlier strains.  
Consequently, current influenza vaccines must be updated frequently in an attempt to match the 
antigenic profiles of vaccine strains to those of circulating strains.  However, the existing process 
of antigenic determination is imperfect: it fails to consider the effects of receptor binding avidity in 
the interpretation of hemagglutination inhibition (HAI) assays or the effects of pre-exposure 
history on how a novel virus is viewed antigenically by an altered immune system.  Here, we 
designed a series of experiments to address these issues.  First, we computationally modeled 
how variation in receptor binding avidity could affect the antigenic characterization of historic 
H3N2 strains and experimentally demonstrated that single point mutations in HA can skew HAI 
titers without actually affecting antibody binding.  Additionally, using the same H3N2 system, we 
showed that a single amino acid mutation can significantly alter the immunodominance of the 
anti-HA antibody response.  We then completed a series of studies to determine how immune 
history influences the specificity of antibody repertoires.  In examining patient serology, we found 
that the specificity of the human antibody response against the 2009 pandemic H1N1 virus 
(pH1N1) was highly correlated with pre-exposure history to different seasonal H1N1 (sH1N1) 
strains during childhood.  Using a ferret model, we demonstrate that the anti-pH1N1 antibody 
response can be shifted to highly conserved epitopes on HA when the animals were primed with 
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sH1N1s that are otherwise antigenically distinct.  Collectively, our studies demonstrate that 
accounting for receptor binding avidity and factors that alter antibody repertoires will improve 
influenza vaccination strategies in the future.   
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CHAPTER 1: Introduction 
Influenza A Basics  
Influenza viruses are negative-sense, single-stranded, segmented RNA viruses of the 
Orthomyxoviridae family that cause rapidly spreading acute respiratory disease in humans.  
Seasonal influenza viruses continue to infect between 5-20% of the United State’s population 
annually, leading to approximately 200,000 hospitalizations and up to 49,000 deaths every year in 
this country alone 1,2.  Three genetically and antigenically distinct types of influenza circulate in 
humans (types A, B, and C, classified based on the nucleoprotein (NP) and matrix (M) 
segments). Of these, type A causes the vast majority of severe illness and has been responsible 
for all the influenza pandemics, highlighted by the 1918 ‘Spanish flu’ that caused up to 50 million 
deaths in just a single season 3,4.  Influenza A viruses are further classified into subtypes based 
on their viral surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA).  To date, there 
have been 17 HA subtypes and 10 NA subtypes that have been identified 5.  The pandemics of 
1918, 1977, and the most recent 2009 pandemic were all caused by H1N1 strains while the 1957 
and 1968 pandemics were the results of H2N2 and H3N2 strains respectively 6.  HA mediates the 
initial entry steps of viral infection, which include attachment to terminally linked sialic acid on host 
cells and the subsequent pH induced membrane fusion following endocytosis 7.  And as the most 
abundant and accessible virally encoded surface protein on the virion, HA is also the primary 
target of neutralizing antibodies (Abs) against influenza 7,8.  NA, on the other hand, facilitates 
virus release and transmission by cleaving the same sialic acid moieties off host cells and 
budding virions following viral replication 9.   
The 17 known subtypes of influenza HA can be categorized into two broad phylogenetic 
groups.  Among the most studied and clinically relevant subtypes, H1, H2, H5, and H9 belong to 
group 1, while H3 and H7 belong to group 2 6.  Intra-subtype HA amino-acid variation remains 
under 20%, whereas inter-subtype variation can be as high as 70% 10.  All subtypes of influenza 
HAs are expressed as homotrimers on viral membranes.  Each identical monomer of trimeric HA 
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is synthesized as a single precursor, HA0, and must be activated via proteolytic cleavage into 
HA1 and HA2 subunits 7.  HA2 forms the relatively conserved membrane-proximal stem of the HA 
involved in endosomal membrane fusion.  In contrast, HA1 mostly forms the more antigenically 
variable membrane-distal head of HA that contains the sialic acid binding pocket.  Several 
structure studies have identified the 130-loop, the 220-loop, the 190-α-helix, and the highly 
conserved residues Y98, W153, H183, and Y195 as being crucial for sialic acid binding 7.   
Different influenza strains preferentially recognize either α2,3-galactose or α2,6-galactose 
linked terminal sialic acids.  Much of this variation in specificity has been shown to be host 
species-specific 11,12.  Waterfowl serve as the reservoir for most influenza A subtypes, and unlike 
in mammalian hosts, influenza results in an enteric rather than respiratory infection in birds.  
Consistent with the fact that α2,3-linked sialic acids predominate in the enteric tracts of avian 
hosts, avian derived influenza viruses have consistently been show to have α2,3-Gal specificity.  
In contrast, human viruses prefer α2,6-linked sialic acids, as they are the more common receptor 
in the human upper respiratory tract 13,14.  Importantly, only a few key amino acid changes in HA, 
such as residues 226 and 228 for H3 HAs and residues 190 and 225 for H1 HAs, are needed to 
alter the preferential binding specificity of most virus strains 15.  Thus not surprisingly, many 
human clinical isolates acquire adaptive mutations when passaged in either mammalian cells or 
embryonated eggs 16,17.   
Regardless of subtype or sialic acid linkage specificity, all influenza HAs bind their 
receptors with relatively low affinity, with dissociation constants in the millimolar range 18,19.  
Furthermore, analysis of the cooperative kinetic seen in HA mediated membrane fusion also 
indicate that multiple HAs are required for the process 20.  This, along with the simple observation 
that the envelope of each virion is densely packed with up to 400 HA trimmers 21, suggests that 
influenza viral entry is likely mediated by the simultaneous interaction of numerous HAs and their 
sialic acid terminated receptors.  These considerations must be appreciated in evaluating the 
complex interactions between influenza viruses, cells, and neutralizing antibodies against HA.   
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Antigenic Drift 
Almost all children are exposed to type A influenza very early in life either through 
infection or vaccination 22.  Following each exposure, neutralizing Abs against the viral surface 
glycoproteins HA and NA are generated, which have been shown to be a correlate of protection 
against the same strain 23.  However, despite evidence that these antibodies continue to persist 
even decades later, most humans are repeatedly infected with different influenza strains 
throughout their lifetime 24,25.  This lack of protection against variant strains is largely attributed to 
a process called antigenic drift, in which the HA and NA glycoproteins continuously accumulate 
mutations and undergo antigenic change to favor variants that are capable of evading existing 
immunity 26,27.  Furthermore, antigenically novel HAs can be occasionally introduced into the 
human population through subtype genome segment rearrangement or zoonotic transmission, 
such as the case with the most recent 2009 pandemic.  Consequently, influenza vaccine strains 
must be updated frequently to keep up with newly circulating strains 8,28.   
Although the antigenic properties of HA and the mechanisms that promote antigenic drift 
have been extensively studied, the accurate identification of antigenic variants remains a 
challenge.  While NA also contains epitopes that undergo natural selection driven by immune or 
drug pressure 29, the receptor binding domain containing HA1 subunit of HA has been shown to 
be under the greatest positive selection pressure 30,31.  In classical mapping experiments, four 
topographically distinct clusters of surface amino acids in the HA1 of H1 subtype HA (Sa, Sb, Ca, 
and Cb) were identified as major binding sites for monoclonal antibodies (mAbs) with high 
neutralizing activity 32.  Similarly, five comparable sites were identified for the H3 type HA, 
designated A-E 33-35.  No single antibody binds the entirety of such a defined antigenic site, but 
competition experiments suggest that many antibody binding epitopes in the same site are 
physically overlapping 32,34.  Importantly, protruding loop-like structures are a common dominating 
feature of these defined antigenic sites 36.  Because these loops do not directly contribute to the 
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structural function of HA (sialic acid binding and membrane fusion), it is thought that mutations at 
these sites are usually tolerated with minimal fitness cost to the virus.   
When grown in the presence of a single anti-HA monoclonal antibody, influenza viruses 
typically acquire single amino acid mutations that directly abrogate binding of the selecting Ab 32.  
Crystallography studies have confirmed that these HA point mutations locally distort a single 
antigenic site without affecting the structures of other antigenic sites 33,37.  Thus while a single 
point mutation can affect the binding of many mAbs with specificity for that site, binding of mAbs 
with specificity for the other antigenic sites are unaffected 38.  Of particular interest to the work 
presented here, many of these mutations not only result in antibody escape, but also influence 
virus receptor binding avidity and specificity 39-41.   
Furthermore, the importance of these antigenic sites has been validated by the natural 
evolution of antigenic drift.  Analysis of H3N2 sequences form 1968-2010 revealed that 63 of the 
329 residues in HA1 have undergone amino acid changes, and of those, 86% are clustered into 
the defined antigenic sites 42.  In addition, the existence of immunodominant antigenic sites is 
supported by the observation that mutations at just 18 residues, all located in either antigenic 
sites A or B, were responsible for 35% of all amino acid replacements seen in H3 HA1s.  With a 
fixation rate of 0.053 substitutions per site per year, these 18 positively selected codons were 
found to acquire mutations 35 times more frequently than other codons in circulating strains 30,43.  
Historically, H3N2s have had faster drift rates compared to H1N1s and influenza B, often with a 
single dominant lineage in circulation.  Because of the relative short survival times of side 
lineages, the evolutionary tree for H3N2 subtype viruses appears linear 43.  In contrast, multiple 
lineages or clades of H1N1s may co-circulate in the human population during any season 44.  
Such differences between the evolution of influenza types and subtypes remain largely 
unexplained.  However, computational models suggest that cross-immunity against strains within 
a subtype as well as immunological interactions between subtypes within the human population 
likely play a significant role 43. In addition, while some lab-identified antigenically drifted variants 
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manage to become widely circulating strains, most fail to spread and establish viable evolutionary 
lineages despite their ability to escape reference ferret sera.  Incomplete understanding of why 
certain lab-identified drift variants are more likely to become the next predominant strain in 
circulation than others is one of the major reasons why vaccine mismatches occur.   
Antigenic drift enables influenza viruses to evade neutralization at a population level, but 
is too slow to result in the evasion of viral clearance following infection of an individual.  
Furthermore, since achieving simultaneous mutations in multiple distinct antigenic sites is beyond 
the error rate of the influenza polymerases 45-47, the question of how viruses mange to cope with 
polyclonal antibodies (pAbs) and circulate in diverse individuals at the population level is raised.  
A popular model theorizes that sequential mutations at the distinct antigenic sites can accumulate 
through transmissions among a subset of the population with narrow monoclonal-like anti-HA Ab 
responses 36,48-50.  However, another model suggests that alterations in viral receptor binding 
avidity may play a significant but underappreciated role in influenza virus immune escape from 
pAbs.  In in vitro and in vivo mouse model studies of a highly mouse-adapted H1N1 virus, the 
presence of sub-saturating pAbs selected for escape variants that contained only a single point 
mutation in HA 40,41.  Despite the observation that these single amino acid changes only minimally 
altered pAb binding, each mutant virus was able to effectively escape pAb neutralization by 
increasing its receptor binding avidity.  This should not be surprising considering that 1) most anti-
HA neutralizing Abs function by interfering with HA’s interaction with sialic acid receptors 7,51, and 
2) influenza viral entry is dependent on the overall avidity between virus and host cell contributed 
by numerous low affinity HA-sialic acid interactions 18,19.  Furthermore, when these high-avidity 
viruses were sequentially passaged in naïve mice lacking pre-existing pAbs, secondary HA 
mutations quickly arose to restore baseline receptor binding avidity levels 40.  Importantly, just as 
mAb selected antigenic mutations often simultaneously alter receptor binding, pAb selected 
receptor binding avidity altering mutations can also alter mAb binding towards specific HA 
antigenic sites.  These results suggest that within an individual host, changes in receptor binding 
avidity can contribute to the accumulation of HA mutations responsible for antigenic drift.  
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However, there has been no study addressing the variation in receptor binding avidity among 
circulating human viruses and its relationship to neutralizing Ab escape, antigenic drift, and 
vaccine failure in the human population. 
In addition to point mutations that directly reduce antibody binding or alter receptor 
binding, HA has also taken advantage of glycosylation as a means to evade neutralizing 
antibodies.  Since the immune system is unable to differentiate oligosaccharides linked to self 
proteins versus those linked to viral proteins, the addition of N-glycosylation sites (NGS) can both 
sterically inhibit existing antibodies from accessing their binding footprint on HA and shield nearby 
epitopes from inducing de novo antibody responses 52-54.  Considering these immune evasion 
properties, it is not surprising that both H1N1s and H3N2s gained additional NGS after 
introduction to the human population 55-57.  But increased glycosylation is not without its costs for 
the virus.  Additional NGS generally lowers the binding avidity of the virus, through either steric 
hindrance of HA binding to sialic acid terminated receptors or decrease of overall virus surface 
charge 58,59.  However, the ever adaptable HA can often overcome these fitness costs associated 
with NGS and maintain its reduced antigenic profile through compensatory mutations 59.  Taken 
together, the currently body of knowledge strongly supports the assertion that the HA of human 
influenza strains can evade antibody neutralization by a wide variety of mechanisms.   
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Relating Antigenic Drift to Vaccine Efficacy  
It is generally accepted that for the current influenza vaccination strategy to be effective, 
there needs to be a close antigenic match between the chosen vaccine strain and the 
predominant circulating strain in any given influenza season.  The combination of complete 
vaccine mismatch and widespread circulation of antigenically drifted strains can result in 
significant epidemiological and economical consequences.  This was most notable for the1997-
1998 influenza season, when an antigenic mismatch of the H3 subtype component resulted in 
vaccine responses that were no better than placebo 60.  This failure became even more striking 
when vaccine efficacy jumped to 86% in the following season following the update to 
A/Sydney/5/1997 (H3N2) to match the antigenicity of strains in circulation 60.  However, the 
relationship between how well vaccine strains match in antigenicity to circulating strains and 
vaccine efficacy is not always consistent.  Paradoxically, several studies have found vaccine 
efficacy to be higher in some years against antigenically drifted strains than in other years with 
well-matched strains 61-63.  Taken together, it is evident that although good antigenic matches are 
generally correlated with higher efficacy, cross-protection against mismatched circulating strains 
can be achieved in certain cases.  Understanding how such cross-protection arise despite 
apparent antigenic mismatch may prove key in improving vaccination against influenza. 
Further confounding our understanding of the relationship between antigenic drift and 
vaccine effectiveness is the observation that the same vaccine can range widely in effectiveness 
among different individuals.  In general, age seems to be a major determinant of vaccine efficacy.  
Meta-analysis suggests that the highest responses are seen in children aged 6 month to 7 years 
while negligible protection is seen in those 65 or older with current vaccines 64,65.  Unfortunately 
this elderly age cohort is also the most susceptible to influenza infection and influenza related 
morbidity and mortality during typical seasonal influenza epidemics 66,67.  Uncovering the 
mechanism behind varying vaccine responses in different individuals remains an area of active 
research.  
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Original Antigenic Sin 
As early as the 1950s, it was noted that upon exposure to antigenically distinct influenza 
strains, the human immune system preferentially mounts Ab responses to previously exposed 
strains at the expense of responses to novel, protective epitopes found exclusively in the new 
strain 68,69.  This process, termed ‘original antigenic sin’ by Thomas Francis Jr., has been 
demonstrated in several animal models and has been proposed to contribute to vaccine failures 
in individuals with previous influenza exposure 70-74.  Consistent with the earlier work, a recent 
study found that antibody titers to influenza A H3N2 in humans follow a pattern of antigenic 
seniority, in that titers are highest against strains that circulated when individuals are 5–10 years 
of age, but then decline steadily thereafter later strains 75.  Understanding why we produce 
progressively fewer novel antibodies specific to each subsequent influenza exposure should be of 
great importance to the influenza vaccine field.   
Elegant absorption experiments conducted in the 1960s and 70s demonstrated that 
original antigenic sin-induced Abs are directed against viral epitopes that are conserved between 
heterologous viruses 69,71.  More recent advances allowing for the analysis of human mAbs 
isolated from antibody-secreting plasma cells following exposure to the novel 2009 pandemic 
H1N1 (pH1N1) yielded similar conclusions 76-78.  Many somatic mutations were seen in the 
immunoglobulin genes of the expanding plasmablasts reactive to pH1N1, which are indicative of 
recall B cell responses.  Furthermore, most of these pH1N1-induced mAbs bind with high affinity 
to older circulating sH1N1 strains.  However, the mechanism that suppresses the development of 
novel strain specific Abs are largely unknown, although competition between antigen-specific 
memory and naïve B cells has been proposed as a contributing factor 74. 
9	  
	  
The 2009 Pandemic H1N1 
Seasonal H1N1 (sH1N1) viruses have been circulating continuously alongside H3N2s in 
the human population since their reemergence in 1977.  Then in the spring of 2009, a novel 
swine origin reassortant H1N1 virus emerged from Mexico and the United States and quickly 
spread among humans worldwide, resulting in the first influenza pandemic of the 21st century 
15,79,80.  Clinically, most human cases of the 2009 pH1N1 resulted in mild upper respiratory 
illnesses, but an appreciable number of severe cases were seen in young, healthy individuals 
without the typical risk factors associated with increased morbidity and mortality due to seasonal 
influenza infections 81-83.  Among different age groups, children experienced the highest infection 
rate, but low mortality rate, while the elderly experienced low infection rate but high case-fatality 
rate 82-84.   
Evolutionary analysis revealed the new virus to contain a reassortment of human, swine, 
and avian gene segments 85,86.  The HA, NP, and NS genes were of classical swine origin, the 
NA and M genes were of a Eurasian avian-like swine lineage, and the PB2 and PA genes were of 
swine triple reassortant lineages with a North American avian origin.  Only the PB1 gene had 
been previously seen by humans (in H3N2 viruses), before becoming incorporated in the swine 
triple reassortant lineage.  Consistent with previous pandemics involving novel influenza viruses, 
pH1N1 quickly displaced existing sH1N1 viruses in circulation 87.  Molecular evolutionary 
analyses has since revealed two major clusters of the pH1N1, with only cluster II variants 
persisting past 2009 in circulation 88.   
Unlike previous influenza pandemics, this new pandemic did not involve a change in the 
HA subtype.  Although still categorized as an H1N1, widespread amino acid differences are 
present when comparing pH1N1 to recent sH1N1 strains, especially in the four antigenic sites 
(Sa, Sb, Ca and Cb) of HA1 85.  However, several structural comparison studies revealed 
significant similarities between the HA of the new 2009 pH1N1 virus and the HAs of H1N1 viruses 
that circulated during the first half of the 20th century, including the 1918 pandemic H1N1 
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virus 88,89.  Consistent with this, cross-reactive antibodies to pH1N1 have been found in the 
elderly population even before exposure to the new strain 90.  Through a combination of natural 
exposure and widespread vaccination using A/California/7/2009 as the vaccine strain, population 
immunity against pH1N1 quickly rose following the pandemic 84.  Recent studies on the humoral 
response of representative human patients either infected or vaccinated with pH1N1 revealed 
some surprising findings.  The majority of pH1N1 HA reactive mAbs derived from these patients 
were found to have cross-reactivity against several sH1N1 strains, despite the significant 
antigenic differences among the viruses 77,78.  Furthermore, nearly all of these pH1N1 specific 
mAbs were class switched and showed extensive affinity maturation, indicating that they were 
likely a result of recalled memory B cell responses 77,78.  These findings are in stark contrast to 
the lack of significant cross-protection seen with repeated sH1N1 exposure.  Understanding the 
mechanisms responsible for development of these cross-reactive antibody repertoires following 
pH1N1 exposure could provide significant insight toward the development of a universal vaccine.   
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Current State of Antigenic Drift Determination and Vaccine Strain Selection 
Vaccine efficacy against influenza is largely dependent on two factors: 1) the level of anti-
influenza neutralizing Abs elicited by the vaccine, and 2) the degree to which those Abs are 
protective against currently circulating and future strains.  The later will be the focus of this 
dissertation and is further dependent on the antigenic differences between the vaccine strain and 
challenge strains, and whether those differences are relevant in the context of the specificity of 
the Ab repertoire elicited by the vaccine.   
The hemagglutination inhibition (HAI) assay has long been used to characterize the 
antigenic properties of influenza strains, as it can be completed in a relatively high-throughput, 
inexpensive manner in laboratories across the world with readily available reagents 91-93.  The 
assay measures the ability of HA-specific Abs in sera to inhibit the agglutination of red blood cells 
by influenza viruses upon HA binding to sialic acid terminated receptors on those cells (Fig. 1.1).  
Thus intrinsically, the assay is dependent on both the binding avidity of anti-HA antibodies for the 
virus and the receptor binding avidity of virus for red blood cells.  Additionally, the HAI assay is 
unaffected by antibodies that do not interfere with receptor binding, including those that provide 
neutralizing protection by binding to the stem of HA and inhibiting membrane fusion.  
The WHO established the Global Influenza Surveillance Network (GISN) in 1952 to 
monitor the spread of antigenically distinct viral strains.  This surveillance team, consisting of over 
136 National Influenza Centers in 106 countries, characterizes thousands of viral isolates every 
year 93,94.  Upon collection, each strain’s antigenic profile is determined using the HAI assay 
against reference sera generated in ferrets infected with previous representative strains.  
Additionally, a subset of the strains’ genomes is further sequenced.  The combined antigenic, 
genetic, and epidemiological data, along with practical consideration such as growth efficiency in 
egg, are used to select the seed strain for vaccine production.  Current annual influenza vaccines 
contain three different strains, one for H3N2, one for H1N1, and one for influenza type B.  For the 
northern hemisphere, the recommendations for the vaccine strains are usually made in February, 
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some nine months ahead the start of the typical influenza season in November to allow adequate 
time for vaccine manufacturing.  However, despite these considerable efforts, the process of 
vaccine strain selection remains imprecise and mismatches still periodically occur.   
A major contributing variable in the suboptimal selection of vaccine strains lies in the 
interpretation of HAI data.  Although raw HAI data offer a good approximation of the antigenic 
differences between the strain used to generate the references sera and related strains, they are 
generally unsuitable for quantitative determinations, even in the hands of experts.  A landmark 
advancement in the interpretation of HAI data was the use of antigenic cartography to spatially 
visualize the relative antigenic distance between different strains and reference sera sets in a 2-D 
antigenic map 95.  These maps showed that antigenically related viruses can be grouped into 
distinct ‘antigenic clusters’ over time and that large antigenic changes resulting in the formation of 
new antigenic clusters occur every few years.  Importantly, when analyzed against the 
phylogenetic data from the same strains, specific HA amino acid substitutions that correspond to 
transitions to new antigenic clusters can be identified 95.  However, despite these advancements, 
current antigenic maps used for vaccine strain selection do not account for variations in viral 
receptor binding avidities in their antigenic determination.  Furthermore, current surveillance is 
based on antisera that are raised in ferrets specifically pre-screened to rule out existing pre-
exposure history to any influenza.  Although this approach would make sense for replicating 
responses in influenza-naïve patients, the vast majority of vaccine recipients have some type of 
pre-exposure to previous strains.  Studies described in the ‘Original Antigenic Sin’ section here 
and elsewhere suggest that these primary ferret antisera may not be representative of human 
immunity.  
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Figure 1.1:  The Hemagglutination Inhibition (HAI) assay.  (A) A schematic of red blood cells 
(RBC) crossed linked by viral bridges responsible for the agglutinated pattern observed when 
influenza viruses are added to RBCs.  (B) A example of a typical HAI assay readout where tear 
streaked RBC pellets indicate antisera dilutions that result in the inhibition viral agglutination of 
RBCs and uniformly opaque wells represent agglutinated RBCs.  In this example, Virus B has a 
reduced HAI titer of 160 compared to the Virus A’s HAI titer of 1280 against the same reference 
antisera.   
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Summary and Statement of Hypotheses  
 Since their first application in the 1940s, seasonal influenza vaccines have greatly 
reduced both the incidence and severity of influenza infections in the human population.  
However, antigenic altering mutations in HA present an ever evolving target that continue to 
challenge the existing approach to antigenic determination and vaccine strain selection.  The HAI 
assay is extensively used in the surveillance of antigenically novel strains, yet current analysis of 
the assay fails to consider two major variables that affect its readout.  First, the receptor binding 
avidities of viral strains are not usually taken into account when interpreting these assays.  The 
studies presented in chapter 2 test the hypothesize that HAI assays incorrectly label viral isolates 
with increased receptor binding avidity as ‘antigenically novel’ and truly antigenically distinct viral 
isolates with low receptor binding avidity as ‘antigenically neutral’.  Second, the effects of varying 
antibody repertoire specificity on antigenic characterization are often underappreciated.  In 
chapter 3, I test the hypothesis that varying pre-exposure history to different past strains can shift 
the specificity of future anti-HA antibody responses in the context of the 2009 pH1N1.  
Collectively these studies will lead to improvements in influenza antigenic determination and 
vaccination strategies.  
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Introduction 
Influenza viruses infect 5-20% of the US population on an annual basis, causing up to 
49,000 deaths every year 1.  Antibodies directed against influenza viruses’ glycoproteins, 
hemagglutinin (HA) and neuraminidase (NA), are very effective in preventing infection.  
Conventional vaccines are designed to elicit these types of antibodies, however influenza viruses 
constantly accumulate mutations in antibody binding sites on HA and NA, a process termed 
‘antigenic drift’.  Vaccines currently licensed by the FDA include only 3 or 4 viral strains (one 
H1N1 influenza A, one H3N2 influenza A, and one or two influenza B viruses).  Devastating 
consequences occur when vaccine strains are antigenically mismatched to circulating strains, as 
was the case during the 2003-04 season 96.   
The WHO established the Global Influenza Surveillance Network in 1952 to monitor the 
spread of antigenically distinct viral strains.  This surveillance team, consisting of over 135 
National Influenza Centers in 105 countries, extensively characterizes thousands of viral isolates 
every year 93.  The antigenic profile of each viral isolate is determined through HAI assays using 
reference sera generated in ferrets.  The 70-year old HAI assay measures reference sera’s ability 
to prevent binding (agglutination) of influenza viruses to red blood cells 97.  This assay is powerful 
since it can be completed in a high-throughput, inexpensive manner in laboratories across the 
world.  The HAI assay, however, is not perfect; viral isolates that bind to red blood cells with high 
avidities can be falsely defined as ‘antigenically novel’ and viral isolates that bind to cells with low 
avidities can be falsely defined as ‘antigenically neutral’, even if they are truly antigenically distinct 
40,41,98. 
Influenza isolates have a wide range of different receptor binding avidities 40,41,98-102, and 
viruses with high receptor binding avidity can escape antibody responses in HAI assays by 
attaching to cells more efficiently 40,41,98,100.  However, vaccines should not necessarily be 
updated when viruses acquire mutations that increase viral receptor binding avidity, because 
many times these mutations result in limited antigenic changes 40,41,98,100.  In the 1940’s and 50’s, 
17	  
	  
it was quickly noted that changes in viral receptor binding avidity can impact HAI assays 91,103, 
however the WHO still does not systematically account for this when interpreting HAI data and 
making vaccine strain recommendations.  Recent thermodynamic models have proposed how 
viral receptor avidity might influence HAI data 104, but to our knowledge, no method to correct HAI 
data for receptor variation has been systematically tested in experimental systems. 
Smith et al. created antigenic maps using HAI data generated with 273 human H3N2 viral 
isolates and 79 post-infection ferret antisera 95.  This study showed that viruses can be grouped 
into distinct ‘antigenic clusters’ over time and that large antigenic changes occur every few years.  
Importantly, this analysis identified specific HA amino acid substitutions that are responsible for 
transitions to new antigenic clusters.  Many antigenic cluster transitions are caused by amino acid 
substitutions in several antigenic sites.  For example, a new antigenic cluster appearing in 1977 
was caused by 13 amino acid substitutions in all 5 HA antigenic sites and a new antigenic cluster 
in 1997 resulted from 6 mutations in 4 HA antigenic sites 95.  However, some antigenic cluster 
transitions are caused by amino acid substitutions that have disproportionately large antigenic 
effects.  A new cluster that appeared in 1979 was caused by mutations in only 2 antigenic sites, 
and even more striking, antigenic cluster transitions in 1987 and 1992 were caused by a single 
HA amino acid substitution (N145K).  Notably, the Smith et al. analysis did not directly account for 
variations in viral receptor binding avidities. 
We hypothesize that disproportionately large HAI antigenic effects can be caused by 
single HA mutations that alter viral receptor binding avidity.  In the current study, we test this 
hypothesis by creating antigenic maps of human H3N2 viruses that computationally account for 
variation in receptor binding avidities.  We then use reverse-genetics approaches to 
mechanistically determine how a single HA mutation affects antigenic clustering of human H3N2 
viruses. 
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Material and Methods  
Viruses.  Viruses possessing the HA of A/Nanchang/933/95 or A/New York/774/93 were 
rescued via reverse genetics using NA and internal genes of A/Nanchang/933/95.  
A/Nanchang/933/95 (GenBank: AFG72625) has a lysine at position 145 and A/New York/774/93 
(GenBank: ABI21310) has an asparagine at position 145.  We cloned the HA of A/New 
York/774/93 into the pHW2000 plasmid and A/Nanchang/933/95 plasmids were provided by 
Jesse Bloom (Fred Hutchinson Cancer Center).  Single amino acid changes to the HA genes 
were made using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA).  All 
viruses were propagated in MDCK cells and the supernatant was harvested through a 0.45um 
filter (Millipore, Billerica, MA).  The HA genes of viruses were sequenced to verify that additional 
mutations did not arise during propagation. 
Anti-sera.  Ferret antisera were prepared at the AAALAC-accredited company, Spring 
Valley Laboratories (Woodbine, MD) using protocols approved by the Spring Valley Laboratories 
Animal Care and Use Committee.  Ferrets were intranasally infected with 1 x 105 TCID50 of each 
virus in 0.5 ml and bled 14 days later.  All sera samples were pre-treated with receptor destroying 
enzyme (Sigma, St. Louis, MO) overnight at 37 C. 
HAI assay.  As previously described (11), HAI titrations were performed in 96-well round 
plates (BD, Franklin Lakes, NJ).  Sera were treated overnight with receptor destroying enzyme 
(RDE) (Cholera filtrate (Sigma, St. Louis, MO)) to remove non-specific inhibitors.  Sera were 
serially diluted 2-fold and added to 4 agglutinating doses of virus in a total volume of 100 ul.  
Next, 12.5 ul of a 2% (vol/vol) solution of turkey red blood cells (Lampire Biological Laboratories, 
Pipersville, PA) was added.  The sera, virus, and red blood cells were mixed and the assay was 
read out after incubating for 1 hr at room temperature.  HAI titers were recorded as the inverse of 
the highest dilution that inhibited hemagglutination of turkey red blood cells. 
Receptor binding assay.  Turkey red blood cells were pretreated with different amounts 
(0.5-80ug/mL) of RDE (a neuraminidase) for 1 hr at 37 C.  The red blood cells were then washed 
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once with PBS and then 2% (vol/vol) red blood cell solutions were made using PBS.  Next, 12.5 
ul of each 2% solution was added to 4 agglutinating doses of influenza A virus (as determined on 
non-RDE treated red blood cells) in a total volume of 62.5 ul.  Virus and RDE-treated red blood 
cells were allowed to incubate for 1hr at room temperature and then agglutination was measured.  
Data are expressed as the maximal concentration of RDE that still allowed for full agglutination. 
ELISAs.  Sucrose gradient-purified viruses were diluted in PBS and added to 96 well flat 
bottom microtiter plates (Thermo Fisher Scientific, Waltham, MA) at 15 HAU per well.  An H3-
specific mouse monoclonal antibody generated in our laboratory (clone K1-4C10) was used to 
verify that equal amounts of each virus were used in these studies.  After incubation for >15 hr at 
4°C, wells were blocked with PBS-BSA.  Ferret sera were then added (serial 2-fold dilutions) and 
allowed to incubate for 2 hr at room temperature.  After washing, goat anti-ferret HRP antibody 
(Abcam, Cambridge, MA) was then added and allowed to incubate for 1 hr at room temperature.  
After washing, TMB substrate (KPL Biomedical, Gaithersburg, MD) was then added and the 
reaction was stopped by adding HCl and the amount of HRP product was determined using a 
plate reader. 
Antigenic map analysis.  Using a biophysical model of HAI, one may decompose any 
given measured HAI titer, denoted HXY, between virus X and anti-serum raised against virus Y 
into three basic components 104:  
H XY = AYK XY J X  [Eq 1] 
where AY denotes the concentration of Abs found in serum Y, KXY denotes the average affinity of 
those Abs for virus X, and JX is a factor to account for non-antigenic properties of virus X that 
influence the HAI titer.  The primary such non-antigenic factor, provided the assay has controlled 
the concentration of red blood cells and virus, is the avidity of the virus for red blood cells.    
Most existing “antigenic maps” of viral strains do not control for viral receptor binding 
avidity, either implicitly or explicitly.  Such maps are constructed based on the standard “antigenic 
distance” between virus X and virus Y after normalizing HXY by the homologous titer HYY 105,106: 
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An alternative normalization used in the original studies of Smith et al. is the maximum titer raised 
against anti-serum Y in a panel of trial strains 95.  Both of these approaches have the virtue of 
controlling for the concentrations of Abs in serum Y, which would confound estimates of antigenic 
differences between X and Y.  However, according to Eq.  1, this commonly used metric does not 
control for variation in viral receptor binding avidities, because  
d(X,Y ) = log2
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depends on the difference in viral receptor binding avidity between virus X and virus Y (namely, 
the ratio JY / JX). 
To control for receptor binding avidity variation between viral strains, without measuring 
viral receptor binding avidity directly, we used the Archetti-Horsfall antigenic distance metric, 
which requires homologous and heterologous HAI titers for viruses X and Y and 103,107: 
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This measure is approximately independent of the viral receptor binding avidities of viruses X and 
Y (Eq.  4).  We used this simple mathematical fact to estimate antigenic distances among the 
large number of strains that have already been subjected to HAI assays, controlling for avidity 
variation.   
For the purpose of comparing results from the above antigenic distance metrics (d from 
Eq 2 and dAH from Eq 4), antigenic maps were generated using the subset of antigens from Smith 
et al. 95 for which both HXY and HYX are known (Fig. 2.1).  In the case of the standard antigenic 
map (Fig. 2.1A – utilizing d), the configuration of antigenic positions was taken from previous 
work 95.  Further minimizing the cost function starting from this configuration did not affect the 
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conclusions drawn from the map.  The map controlling for variation in viral receptor binding 
avidity (Fig. 2.1B – utilizing dAH) was generated by minimizing (using the method of conjugate 
gradients) the map error function 95, where the target distance between each pair of antigens, X 
and Y, was defined using Eq.  4.  To illustrate the robustness of the maps, we follow previous 
work by presenting the “rigidity confidence area” 95 for each individual antigen in the maps.  Thus, 
for each antigen, all other antigens (and sera in the case of Fig. 2.1A) were held fixed, and the 
sensitivity of the map error function to displacement of the target antigen was determined.  The 
outline of each antigen’s map location indicates an increase in 0.5 of the map error function.  
Colored contours illustrate the rate of error increase for each antigen – from black (zero error) to 
the base color of the antigenic cluster (0.5 error) at the periphery (Fig. 2.1).   
Fig. 2.1 shows that, although the traditional antigenic map (Fig. 2.1A) shares many 
similarities with the antigenic map controlling for viral receptor binding avidity (Fig. 2.1B), there 
are also notable qualitative differences.  To formally quantify these differences, we followed the 
clustering analysis of Smith et al. (Fig. 2.1A), by identifying and comparing the antigenic clusters 
in the map of Fig. 2.1B using k-means clustering with k = 10 95.  For an objective analysis, the 
strains that were placed into antigenic clusters manually in the previous work of Smith et al. 
(BI/628/76, BI/2271/76, TE/1/77, VI/7/87, OK/5/88, and VI/1/88) were excluded from our analysis.  
Of particular interest, our comparison identified key members of the 1989-92 and 1992-95 
clusters that, when viral receptor binding avidity is accounted for, are formally reclassified.  
Specifically, when accounting for viral receptor binding avidity (Fig. 2.1B), the 1989-92 cluster 
gains two members (FI/338/95 and GE/A9509/95) from 1992-95 and the 1992-95 cluster gains 
one member (NL/18/94) from 1989-92.  These changes in clustering were robust with respect to 
the confidence areas around the antigenic positions in the map.   
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Results  
Generation of antigenic maps that account for changes in viral receptor binding 
avidity.  Classical antigenic maps are constructed by finding a two-dimensional embedding of 
viral isolates and antisera that respects the antigenic “distances” among them as determined from 
HAI measurements.  To address whether variation in viral receptor binding avidities can affect 
antigenic cluster transitions, we used the Archetti-Horsfall antigenic distance metric 103,107 to 
computationally account for variation in viral receptor binding avidities of the viruses used in the 
Smith et al study 95.  This metric requires both homologous and heterologous titers for all isolates 
being compared (see Material and Methods), and it provides a computational correction for 
variation in receptor-binding avidities.  Upon generating a new antigenic map using the Archetti-
Horsfall metric (Fig. 2.1), we observed that a previously identified antigenic cluster that was 
triggered in 1992-95 by the single N145K HA mutation splits into two, such that some isolates 
previously identified in one cluster move to the other cluster, and vice versa.  This qualitative 
observation was verified in a formal k-means clustering analysis (see Materials and Methods).  
The interdigitation of strains previously characterized as antigenically distinct suggests that 
variation in viral receptor binding avidity, as opposed to genuine antigenic change, influenced 
these antigenic groupings in the original map by Smith et al. 95.  Although the most dramatic 
differences between the two different types of map involved the 1992-95 clusters, there were 
other notable differences in the receptor binding avidity-adjusted antigenic map (Fig. 2.1).  For 
example, the 1987-89, 1979-87, and 1997-2002 clusters became more compact and the 1995-97 
cluster became more dispersed once adjusting for variation in viral receptor binding avidities.  
Some antigenic clusters (such as the 1968-1972 cluster) contained relatively limited amounts of 
data, which introduced large confidence regions in their 2-D embeddings.  These data strongly 
support the hypothesis that antigenic positioning of viral isolates is influenced, at least in part, by 
changes in viral receptor binding avidity. 
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N145K HA mutation increases receptor binding avidity of H3N2 strains.  We 
experimentally focused on the N145K HA mutation that is associated with an antigenic cluster 
transition between 1992-1995 in conventional antigenic maps.  Amino acid position 145 is located 
in antigenic site A of H3, adjacent to the sialic acid binding domain (Fig. 2.2).  The N145K HA 
mutation is not predicted to result in a loss of a glycosylation site.  To address if HA amino acid 
position 145 alters receptor binding avidity, we used reverse genetics to introduce an N145K 
mutation into the HA of A/New York/774/93 and a K145N mutation into the HA of 
A/Nanchang/933/95.  On both genetic backgrounds, viruses possessing K145 HA bound to red 
blood cells more avidly compared to viruses containing N145 HA (Fig. 2.3).  The A/New 
York/774/93 virus possessing K145 HA bound to red blood cells treated with 16-fold higher RDE 
concentrations compared to the same virus possessing N145 HA, and the A/Nanchang/933/95 
virus possessing K145 HA bound to red blood cells treated with 4-fold higher RDE concentrations 
compared to the same virus possessing N145 HA (Fig. 2.3).   
N145K HA mutation does not physically prevent antibody binding.  HAI titers are 
dependent on interactions between antibodies and virus and interactions between virus and 
receptors on red blood cell surfaces.  Therefore, HAI titers can be decreased by HA mutations 
that reduce antibody binding to virus and/or increase virus binding to red blood cells 40,41,98,100.  
Consistent with data generated by Smith et al. 95, virus possessing K145 HA escaped ferret 
antisera generated against virus possessing N145 HA 2-fold in HAI assays (Table 2.1).  To 
differentiate how the N145K HA mutation promotes viral escape in HAI assays, we introduced a 
secondary I226V HA mutation, which has previously been shown to influence receptor binding 
properties 16,108,109.  Introduction of the I226V HA mutation decreased receptor binding avidity of 
A/Nanchang/933/95 virus possessing K145 HA (Fig. 2.3B).  We used this double mutant virus to 
determine if the N145K mutation promotes HAI escape through increasing receptor binding 
avidity or through significant antigenic change.  If the N145K HA mutation causes a significant 
antigenic change, the double mutant virus would be expected to escape sera in HAI assays 
despite having lower receptor binding avidity.  However, A/Nanchang/933/1995 possessing both 
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K145 and the I226V HA mutation failed to escape ferret antisera generated against virus 
possessing N145 HA in HAI assays (Table 2.1). 
Direct antibody binding ELISA assays confirmed that N145K does not result in a 
significant antigenic change; sera generated against a virus possessing N145 HA bound similarly 
to viruses possessing either N145 or K145 HA (Fig. 2.4A).  As expected based on the buried 
location of amino acid 226 (Fig. 2.2), sera generated against a virus possessing N145 HA also 
bound efficiently to a virus possessing both the N145K and I226V mutations (Fig. 2.4A).  Taken 
together, these data indicate that the N145K mutation promotes HAI escape by increasing viral 
receptor binding avidity and not by preventing antibody binding. 
N145K HA mutation causes an asymmetric antigenic change.  We anticipated that 
viruses possessing the N145K HA mutation would ‘escape’ homologous antisera (sera generated 
against viruses possessing K145), since the N145K mutation promotes escape of heterologous 
antisera (sera generated against viruses possessing N145) by increasing receptor binding avidity.  
However, despite having lower receptor binding avidity (Fig. 2.3B), viruses possessing N145 HA 
escaped antisera generated against virus possessing K145 HA in HAI assays (Table 2.1).  
Viruses possessing both K145 and V226 HA actually had slightly higher HAI titers compared to 
viruses possessing only K145 HA (Table 2.1), consistent with the observation that the I226V HA 
mutation decreases receptor binding avidity (Fig. 2.3B).  Direct antibody binding ELISA assays 
confirmed that antisera generated against viruses possessing K145 HA binds poorly to viruses 
possessing N145 HA (Fig. 2.4B). 
Collectively, these data suggest that the N145K HA mutation leads to an asymmetric 
antigenic change.  Antibody responses generated against viruses possessing N145 HA are 
directed against regions other than amino acid 145, and viruses possessing the N145K HA 
mutation escape these antibodies by binding to cells with a greater avidity.  Conversely, a large 
portion of antibodies generated against viruses possessing K145 HA are directed against an 
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epitope involving amino acid 145, and viruses possessing N145 HA escape these antibodies by 
physically altering this epitope. 
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Discussion 
The choice of seasonal vaccine composition is naturally a complicated decision involving 
many factors, scientific and practical alike – e.g. the ability of strains to grow in eggs, the 
production readiness of various vaccine manufacturers, and recent epidemiological data on 
spatial spread.  This decision is heavily influenced by antigenicity studies using HAI assays.  
Recent advances in antigenic cartography 95,110,111 have greatly improved our interpretation of HAI 
data.  However, even though the outcome of the HAI assay, for a given viral isolate and serum, 
clearly depends on a dynamic competition of virus-antibody interactions with virus-cell 
interactions, there is a tendency to tacitly assume that standard notions of  “antigenic distance” 
relate solely to virus-antibody binding affinity 112-114.  Variation in viral receptor binding avidity has 
not been taken into account when creating antigenic maps, and the WHO does not systematically 
account for virus-red blood cell receptor binding avidities when interpreting HAI data and making 
vaccine strain recommendations. 
It has been commonly thought that influenza viruses primarily escape antibody responses 
by acquiring mutations that physically abrogate antibody binding.  Indeed, when grown in the 
presence of a single anti-HA monoclonal antibody in ovo, influenza viruses readily acquire a 
single HA mutation that physically prevents binding of the selecting monoclonal antibody 32.  
However recent mechanistic studies suggest that antigenic drift of influenza viruses might be 
heavily dependent on mutations that alter both antigenicity and receptor binding avidity 40.  In 
these studies, single HA mutations that increase receptor binding avidity quickly emerged when 
virus was passaged in vivo in vaccinated mice.  Influenza neutralization efficiency is therefore 
dependent on antibody binding affinity to HA and HA binding avidity to cellular receptors.  Since 
receptor-altering mutations are located on exposed regions of HA, many of these mutations 
simultaneously alter antigenic sites 40. 
It is important to note that these previous receptor binding avidity studies were completed 
in a mouse model 40.  It is unknown how changes in receptor binding avidity affect antigenic drift 
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of human influenza viruses but it is very interesting that H3N2 viruses possessing the N145K HA 
mutation (which increases receptor binding avidity) accumulated the secondary I226V HA 
mutation (which decreases receptor binding avidity) before widely circulating in the state of New 
York 115,116.  High-avidity viruses can escape antibodies by efficiently entering cells, however 
there is a fitness-cost associated with increased avidity.  This fitness-cost is likely due to 
imbalances between viral entry and viral release since high-avidity virions are not efficiently 
released from cells at later stages of the viral lifecycle.  Consistent with this, high-avidity viruses 
quickly accumulate secondary mutations that decrease receptor binding avidity when passaged in 
naïve mice 40.  Computational studies have recently identified pairs of epistatic HA mutations 117 
and it remains to be determined if these mutations alter receptor binding avidity. 
Asymmetric HAI assays have been reported 98,118, but to our knowledge, our study is the 
first to document that a single HA mutation can substantially change the immunodominance of 
anti-influenza antibody responses.  The addition of the positively charged lysine at amino acid 
145 might dramatically change the structure of antigenic site A of H3.  It is unusual that position 
145 has alternated between asparagine and lysine four times since 1975.  We speculate that 
viruses possessing K145 HA have only appeared transiently in the human population due to 
heightened immunodominance of antigenic site A in these viruses. 
Regardless of the mechanism(s) that promote antigenic drift of influenza viruses, it is 
clear that there is variation in receptor binding avidity among influenza strains 40,41,98-102.  
Therefore, we believe that it is imperative to consider receptor binding avidity measurements 
when constructing and interpreting antigenic maps based on HAI data.  Our new antigenic maps 
that account for variation in viral receptor binding avidities strongly support the hypothesis that 
antigenic clustering is influenced by changes in receptor binding avidity, and we have used 
experimental approaches to validate that the 1992-1995 cluster transition is impacted by a single 
amino acid substitution that alters receptor binding avidity.   
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Figure 2.1: Conventional and receptor binding avidity-adjusted antigenic maps.  (A) 
Conventional antigenic maps of H3N2 viruses circulating from 1968-2002 were created using HAI 
data from Smith et al. (23).  Pink and green circles are drawn around the isolates belonging to the 
1989-92 and 1992-95 clusters, respectively, as defined by Smith et al. (23).  Variation in viral 
receptor binding avidity was accounted for by using the Archetti-Horsfall equation (see Material 
and Methods).  (B) New antigenic maps were created using the Smith et al. HAI data after 
adjusting for inferred receptor binding avidities.  Pink and green circles are drawn around new (k-
means) clusters for which the majority of isolates correspond to the Smith et al. 1989-92 and 
1992-95 clusters, respectively.  The x and y axes represent antigenic distance, and the spacing 
between grid lines corresponds to 2-fold dilutions of antisera in HAI assays.  Rigidity confidence 
areas are shown for each cluster. 
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Figure 2.2: Location of HA mutations associated with the 1992-95 antigenic cluster 
transition.  Amino acids 145 (gold) and 226 (purple) are highlighted on the X-31 H3 structure 
(PDB 1HGG).  The glycan receptor is shown in black. 
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Figure 2.3: The N145K HA mutation increases receptor binding avidity of H3N2 viruses.  
Viruses expressing A/New York/774/93 (A) or A/Nanchang/933/95 (B) HA with either asparagine 
(N) or lysine (K) at amino acid 145 were generated by reverse genetics.  A secondary I226V HA 
mutation was also introduced into A/Nanchang/933/95 viruses that possessed K145 (B).  Relative 
viral receptor binding avidities were determined by hemagglutination of red blood cells pre-treated 
with increasing amounts of neuraminidase (RDE).  Data are expressed as the maximal amount of 
neuraminidase that allowed full agglutination.  Mean and SEM of triplicate samples are shown.  
The data are representative of three independent experiments. 
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Figure 2.4: The N145K HA mutation leads to an asymmetric antigenic change.  Direct 
antibody binding to different viruses was determined by ELISA using sera isolated from ferrets 
infected with A/Nanchang/933/95 possessing N145 HA (A) or K145 (B).  Mean and SEM of 
triplicate samples are shown.  The data are representative of three independent experiments. 
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Table 2.1:  HAI titers using A/Nanchang/933/95 variants. 
 
aHAI assays were performed using turkey RBCs.  HAI titers are expressed as the inverse of the 
highest serum dilution that inhibited hemagglutination.  Data are representative of 4 independent 
experiments.  Bold = homologous titer 
bReceptor avidity values shown in Figure 2.3. 
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Introduction 
Most influenza pandemics occur when a new subtype of virus enters the human 
population.  Once introduced into the human population, influenza viruses typically accumulate 
mutations in the hemagglutinin (HA) and neuraminidase (NA) glycoproteins, a process called 
‘antigenic drift’.  An H1N1 influenza virus strain caused a pandemic in 2009 86 even though H1N1 
viruses have circulated in humans from 1918-1957 and then again from 1977-2009.  The 2009 
pandemic H1N1 (pH1N1) strain is antigenically distinct from recently circulating seasonal H1N1 
(sH1N1) strains and is more closely related to older sH1N1 strains 85,119,120.   
Sera isolated from influenza-infected ferrets are currently utilized for surveillance of 
antigenically drifted influenza strains 121.  Anti-pH1N1 antibody responses elicited in ferrets are 
focused on the highly variable Sa antigenic site of HA 122.  Conversely, the majority of monoclonal 
antibodies derived from humans infected or vaccinated with pH1N1 are directed against 
conserved regions of the HA stalk and receptor binding domain 77,78,123.  Most of these 
monoclonal antibodies possess many somatic mutations and bind to sH1N1 viruses efficiently, 
which is consistent with the idea that these antibody responses were likely originally primed by 
sH1N1 infection and were later recalled during pH1N1 infection/vaccination 77,78,123-125.  
Understanding the precise events that promote the development of these cross-reactive antibody 
repertoires will aid in developing a ‘universal’ influenza vaccine that targets conserved areas of 
HA. 
Here, we compared the specificity of pH1N1 antibody responses elicited in different aged 
humans.  We find that most individuals born between 1983-1996 elicit pH1N1 antibody responses 
that are dominated against an epitope near the HA receptor binding domain.  Most sH1N1 viruses 
that circulated between 1983-1996 share homology with the pH1N1 virus in this region of HA.  
Antibody responses dominated against this HA epitope were induced following sequential 
infection of ferrets with a 1991 sH1N1 virus and a pH1N1 virus.  Most humans born prior to 1983 
or after 1996 did not mount anti-pH1N1 antibody responses against this HA region.  Importantly, 
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most sH1N1 viruses that circulated prior to 1983 or after 1996 have an amino acid mutation or 
deletion in this HA epitope.   
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Material and Methods 
Viruses.  A/California/07/2009, A/England/195/2009, A/Utah/42/2009, A/Utah/20/2009, 
A/Philippines/2810/2009, and A/South Carolina/18/2009 were kind gifts from Nancy Cox (CDC).  
A/Brisbane/59/2007 and A/Denver/1/1957 were obtained through the NIH Biodefense and 
Emerging Infectious Research Resources Repository, NIAID, NIH (NR-3223 and NR-4229).  
A/Fort Monmouth/1/1947 and A/Puerto Rico/8/1934 viruses were obtained from the Wistar 
Institute Gerhard collection.  A/Texas/36/1991 and A/California/07/2009 viruses with mutant HAs 
were created via reverse genetics.  Single amino acid changes to the HA gene were made using 
the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and confirmed by 
sequence analysis.  All reverse-genetics viruses with A/California/07/2009 HA and NA were 
created using 6 A/Puerto Rico/8/1934 internal genes to enhance virus growth.  Reverse-genetics 
plasmids were kind gifts from Jesse Bloom (Fred Hutchinson Cancer Center).  All viruses 
possessing A/California/07/2009 HA and NA were propagated in MDCK-SIAT1 cells and the 
supernatant was harvested through a 0.45um filter (Millipore, Billerica, MA).  The HA genes of 
these viruses were sequenced to verify that mutations did not arise during propagation. 
Ferret sera.  The following pooled ferret sera (6-9 animals/batch) were obtained through 
the NIH Biodefense and Emerging Infectious Research Resources Repository, NIAID, NIH: anti-
A/California/07/09 (NR-15429), anti-A/Nanchang/8008/2009 (NR-19265), and anti-
Mexico/4108/2009 (NR-19264).  Ferret antisera against A/Fort Monmouth/1/1947 (FR-952) were 
obtained from Influenza Reagent Resource, Influenza Division, WHO Collaborating Center for 
Surveillance, Epidemiology and Control of Influenza, CDC, Atlanta, GA, USA.  Additional ferret 
antisera were produced at the University of Pittsburgh 126 using procedures in accordance with 
the NRC Guide for the Care and Use of Laboratory Animals, the Animal Welfare Act, and the 
CDC/NIH Biosafety in Microbiological and Biomedical Laboratories handbook.  Fitch ferrets 
(female, 6-12 months of age) which were seronegative for circulating H1N1, H3N2, and influenza 
B viruses were purchased from Marshall Farms (Sayre, PA).  Ferrets were infected with 1x106 
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PFU of sH1N1 virus (A/Denver/1/1957, A/Texas/36/1991, or A/Brisbane/ 59/2007) or pH1N1 virus 
(A/California/07/2009) and bled 14 days later.  Other ferrets were sequentially infected with a 
sH1N1 virus (A/Fort Monmouth/1/1947, A/Denver/1/1957, A/Texas/36/1991, or A/Brisbane/ 
59/2007) and then pH1N1 virus.  For these experiments, ferrets were infected with 1x106 PFU of 
sH1N1 and then infected again with 1x106 PFU of pH1N1 virus 84 days later.  These animals 
were bled 14 days later and sera were isolated after centrifugation.   
Human sera.  Studies involving human adults were approved by the Emory University 
and the University of Chicago and studies involving pediatric samples were approved by the 
Institutional Review Board of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 
Milan Italy and carried out in the Department of Maternal and Pediatric Sciences at the University 
of Milan.  These sera were collected in 2009 for previous studies 77,127 and leftover sera were 
used for this study.  Sera were collected at Emory between 10-31 days after onset of influenza 
symptoms 77 and at Milan 28 days after diagnosis of pH1N1 infection 127.  Diagnosis of pH1N1 
influenza infection was determined by PCR.   
Human monoclonal antibodies.  Monoclonal antibodies were generated from antibody-
secreting cells isolated from the peripheral blood mononuclear cells of patients infected with 
pH1N1 in 2009 as described 77.  Antibody-secreting cells were sorted, VH and VK genes were 
amplified and sequenced and cloned into IgG1 cloning vectors, and recombinant antibodies were 
purified from cell supernatant after cotransfecting heavy and light chain plasmids into 293A cells. 
HAI assay.  As previously described 40, HAI titrations were performed in 96-well round 
plates (BD, Franklin Lakes, NJ).  All sera samples were pre-treated with receptor destroying 
enzyme (Sigma).  Sera or monoclonal antibodies were serially diluted 2-fold and added to 4 
agglutinating doses of virus in a total volume of 100 ul.  Next, 12.5 ul of a 2% (vol/vol) turkey 
erythrocyte solution was added.  The sera, virus, and erythrocytes were gently mixed and the 
assay was read out after incubating for 60 min at room temperature.  HAI titers were recorded as 
the inverse of the highest dilution that inhibited hemagglutination of turkey erythrocytes.   
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Flow cytometry-based sera binding assay.  MDCK cells were seeded in 6 wells plates 
at 1.5 x 106 cells per well.  The cells were infected with pH1N1 viruses the next day and 15-18 hrs 
later the infected cells were harvested.  Serial dilutions of sera were added to the cells for 30 
mins at 4 C.  Cells were washed and then anti-ferret FITC antibody (Abcam) was added for 30 
mins at 4 C.  Levels of total HA cell surface expression was monitored by incubating cells with the 
anti-HA stalk monoclonal antibody, 70-1F02.  Flow cytometry was performed and data is 
expressed as mean fluorescent intensity.   
Sequencing.  RNA was extracted from virus using QiAmp viral RNA mini kit (Qiagen).  
The HA gene was amplified using the One-Step RT-PCR kit (Invitrogen), and sequencing was 
performed at the University of Pennsylvania Sequencing Facility. 
Mutant Modeling, Structural Equilibration, and Electrostatic Calculations.  Mutant 
HA structural models were derived from the HA crystal structure from pandemic H1N1 (PDB 
identifier 3LZG).  Wild-type (WT) HA was derived from the PDB (3LZG) by mutating Ala at 
position 198 (H3 numbering) to Thr in the HA1 domain.  We then generated mutants – K133N 
and G158E– from the WT model (mutations to WT were all in the HA1 domain).  Initial 
conformers for the mutated residues and the protonation states of all residues were assigned 
using the PDB2PQR software tool along with the residue pKa prediction software, PROPKA 
(http://propka.ki.ku.dk) 128.  All protein chains (HA1 and HA2) were neutralized by acetylating the 
N-terminus and N-methylating the C-terminus.   
To ensure the reliability of the model structures, we equilibrated each model using 
molecular dynamics (MD) simulation in explicit solvent.  All molecular mechanics calculations and 
MD simulations were performed on the Gordon computer cluster at the San Diego 
Supercomputing Center using the GROMACS package 129 (version 4.5) with the AMBER03 force 
field for protein, ions, and TIP3P model water molecules.  Production runs used a time step of 2.0 
fs.  Configurations of the system were saved every 2 ps for later analysis.  Periodic boundary 
conditions were applied in all three dimensions.  The LINCS algorithm was used to constrain all 
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bonds in the system.  Long range electrostatics were handled using the smooth particle mesh 
Ewald algorithm 130 with a real-space cutoff of 1.0 nm.  Other non-bonded interactions were 
smoothly switched to zero from 0.8 to 0.9 nm.  The temperature was maintained at 300 K using 
the Nose-Hoover scheme with an oscillatory relaxation period of 2.0 ps.  The pressure was 
maintained at 1 atm using the Parrinello-Rahman coupling scheme with a barostat time constant 
of 2.0 ps.  The rectangular simulation box was allowed to scale in size isotropically in order to 
maintain pressure.   
Each model was solvated in a rectangular box of ~100 mM KCl electrolyte, comprising 
38565 water molecules, 69 K+ ions, and 69 Cl- ions.  All ions were initially placed randomly in the 
solvent.  Since all HA mutant models possessed net negative charge (after assignment of residue 
protonation states), we added additional K+ counterions to the solvent to ensure net charge 
neutrality for each simulated system.  Initially, all systems were subjected to 50 steps of steepest 
descents energy minimization, followed by 200 ps of simulation using Berendsen temperature 
and pressure coupling while imposing harmonic position restraints (1000 kJ/mol/nm2) on the 
protein backbone in order to allow water and ions to relax around the protein as the system 
density converged.  We then switched to production run parameters while imposing position 
restraints on the backbone of the HA2 domain only, allowing free equilibration of the HA1 domain.  
Convergence, starting from initial conditions (derived from the 3LZG X-ray structure), was seen 
within 30 ns for the WT and G158E systems.  The K133N mutant system was derived from the 
WT structure after 30 ns of simulation, and simulated for only 10 ns to ensure equilibration.  
Convergence of the root mean square distance deviation (RMSD), after alignment of all HA1 
sidechain atoms from each time step to those of the initial configuration, was seen for all 
simulated systems. 
We used the VMD software interface (http://www.ks.uiuc.edu/Research/vmd) to the 
Adaptive Poisson Boltzmann Solver (APBS version 1.3) 131 for continuum solvent electrostatic 
potential calculation at the inflated molecular surface of the final equilibrated protein configuration 
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for each mutant.  Molecular surfaces were generated using the QuickSurf method at maximum 
surface quality with a resolution of 1.06, radius scale of 1.0, density isovalue of 1.1, and grid 
spacing of 0.5.  Atomic radii and charges were taken from the AMBER03 force field used in the 
MD simulations described above.  We used continuous cubic B-spline boundaries for all dielectric 
and ion-accessibility interfaces, and cubic B-spline discretization of the charge distributions.  
Linearized Poisson-Boltzmann calculations were performed at 300 K with a dielectric constant of 
78.54 for water and 1.00 for the protein interior.  The ion concentrations approximated the model 
concentrations in the explicit solvent simulations (~100 mM). 
Statistical analysis.  Paired t-tests were used to evaluate differences between WT and 
mutant viruses based on log2-transformed titer data.  Fisher’s exact tests were used to compare 
the proportions of samples with at least a 2-fold lower titer to mutant virus than WT virus between 
specified infection groups.  Data were graphed using MS Excel and GraphPad Prism software.   
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Results  
Anti-pH1N1 Sera Produced in Previously Naïve Ferrets are Dominated Against the 
Sa Antigenic Site of HA.  Since entering the human population in 2009, pH1N1 viruses have 
remained antigenically stable and approximately 99% of pH1N1 isolates characterized by the 
CDC in 2012-2013 were antigenically similar to the A/California/07/2009 vaccine strain 
(www.cdc.gov/flu/weekly).  We obtained three rare viral strains from the CDC that efficiently 
escape anti-pH1N1 ferret sera in hemagglutination-inhibition (HAI) assays Table 3.1).  Each of 
these strains possesses a mutation at amino acid residues 158 or 159 in the Sa antigenic site of 
HA (Table 3.2).  Atomistic modeling and electrostatic calculations suggest that the G158E HA 
mutation locally alters the electrostatic properties and shape of the Sa antigenic site (Fig. 3.1).  
Reverse-genetics experiments revealed that a single G158E HA mutation was sufficient to 
promote escape from sera isolated from ferrets infected with the A/California/07/2009 pH1N1 
vaccine strain (Fig. 3.2A, p=0.016 using paired t-test).  These findings are consistent with 
previous studies which demonstrated that anti-pH1N1 ferret sera are dominated against an 
epitope involving amino acids 156, 157, and 158 of the Sa HA antigenic site 122.   
 Unlike ferret antisera, most human anti-pH1N1 monoclonal antibodies are dominated 
against conserved regions of the HA stalk and receptor binding domains 77,78.  HA amino acid 
133, which is located near the receptor binding domain, is a critical contact residue for several 
broadly neutralizing human monoclonal antibodies 132,133.  Most pH1N1 strains have a lysine at 
HA amino acid 133.  We completed additional HAI assays with a pH1N1 virus possessing a 
K133N HA mutation, which is predicted to broadly alter the electrostatic potential on the surface 
surrounding the receptor binding domain (Fig. 3.1).  Unlike pH1N1 viruses with a G158E Sa 
mutation, pH1N1 viruses with a K133N HA mutation were efficiently recognized by anti-pH1N1 
sera produced in ferrets (Fig. 3.2A).  HAI titers using pH1N1 viruses with a K133N HA mutation 
were slightly higher compared to HAI titers using wild-type pH1N1.  The K133N HA mutation 
decreases receptor binding avidity (data not shown) and our previous studies demonstrated that 
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viruses with lower receptor binding avidity can be more easily inhibited in HAI assays 40.  For this 
reason, we completed additional direct antibody binding assays, which are not affected by 
variations in viral receptor binding avidities.  These assays confirmed that anti-pH1N1 sera 
produced in ferrets reacts strongly to wild-type pH1N1 virus and pH1N1 virus with a K133N HA 
mutation, but not to pH1N1 virus with a G158E HA mutation (Fig. 3.2B).   
Different Aged Humans Mount Vastly Different pH1N1 Antibody Responses.  Next, 
we completed HAI assays with sera isolated from pH1N1-infected humans (Fig. 3.3A-C and 
Table 3.3).  Only 11 of 54 human sera samples had reduced HAI titers (at least a 2-fold change) 
to pH1N1 viruses with the G158E Sa mutation.  Of these 11 Sa-specific sera samples, 8 (73%) 
were from individuals with no evidence of sH1N1 pre-exposure, as determined by HAI assays 
using sH1N1 strains from 1957 (A/Denver/1/1957), 1991 (A/Texas/36/1991), and 2007 
(A/Brisbane/59/2007) (Table 3.3).  The 3 Sa-specific samples that exhibited sH1N1 cross-
reactivity were from individuals born prior to 1971 (Table 3.3).  Strikingly, 7 of 8 samples from 
individuals born between 1983-1996 were highly specific to the pH1N1 HA epitope involving K133 
(Fig. 3.3B and Table 3.3) (Fisher’s exact test p-value < 0.001 comparing 1983-1996 sera to sera 
from other time periods).  This time period is noteworthy, since the HAs of most sH1N1 strains 
circulating from 1983-1996 possessed a K133, while the HAs of most sH1N1 strains circulating 
before 1983 and after 1996 had a mutation or deletion at this critical amino acid (Fig. 3.3D).  The 
A/Texas/36/1991 strain possesses K133, whereas A/Denver/1/1957 and A/Brisbane/59/2007 
strains have a deletion at this amino acid.  Notably, 8 of 9 of the K133-specific sera isolated from 
pH1N1-infected humans had high titers against the A/Texas/36/1991 strain (Table 3.3).  Previous 
studies have documented that most humans have high HAI titers against strains that circulated 
early in each individual’s childhood 22.  Therefore, individuals born between 1983-1996 were likely 
exposed to a sH1N1 strain similar to A/Texas/36/1991.  One individual born in 1979 possessed 
K133-specific sera (Table 3.3).  This individual’s first H1N1 exposure likely involved a K133-
possessing sH1N1, since sH1N1 did not widely circulate between 1979-1982 43. 
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Monoclonal Antibodies Derived From pH1N1-infected Humans Bind to a sH1N1 
Virus Possessing K133.  Since our sera samples were collected from humans naturally infected 
with pH1N1, we were unable to obtain sera prior to pH1N1 infection.  To determine if antibody 
secreting cells specific for the K133 HA epitope were actively recruited during pH1N1 exposure, 
we analyzed the specificity of monoclonal antibodies derived from plasmablasts transiently 
expanded in the blood of human adults infected with pH1N1.  We analyzed 4 monoclonal 
antibodies that were previously shown to efficiently recognize pH1N1 in HAI, ELISA, and in vitro 
neutralization assays 77. 
Three of 4 antibodies failed to react with pH1N1 virus expressing the K133N HA mutation 
in HAI assays (Fig. 3.4).  All 3 of the K133-specific antibodies reacted strongly with the 
A/Texas/36/1991 seasonal H1N1 strain, which possesses K133.  Only the EM-4C04 monoclonal 
antibody had reduced reactivity to pH1N1 viruses expressing a G158E HA mutation in the Sa 
antigenic site (Fig. 3.4), which is consistent with previous mapping studies showing that this 
antibody is more strain-specific compared to other human anti-pH1N1 monoclonal antibodies 123.  
None of the 3 K133-specific antibodies reacted with the A/Denver/1/1957 or A/Brisbane/59/2007 
seasonal strains, which have a deletion at amino acid 133 of HA (Fig. 3.4).  Based on this 
reactivity pattern and the observation that the immunoglobulin genes of these antibodies have 
many somatic mutations 77, it is likely that these monoclonal antibodies were derived from 
plasmablasts that were originally primed by sH1N1 viruses similar to A/Texas/36/1991 and then 
later recalled during pH1N1 infection. 
Antibodies Specific For an HA Epitope Involving K133 Can Be Induced in Ferret.  
Based on our HAI assays using sera (Fig. 3.3 and Table 3.3) and monoclonal antibodies (Fig. 
3.4) isolated from humans, we hypothesized that K133 HA-dominated antibody responses could 
be induced by sequential infection with sH1N1 and pH1N1 strains that both possess K133.  To 
address this, we pre-exposed ferrets with different sH1N1 strains circulating from 1947-2007 and 
then we infected these same ferrets with a pH1N1 strain.  Remarkably, sera isolated from 3 
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different ferrets sequentially infected with the sH1N1 strain A/Texas/36/1991 (which possesses 
K133) and the pH1N1 strain were dominated against an HA epitope involving K133 (Fig. 3.5C).  
Sera isolated from pH1N1-infected ferrets that were previously exposed to either A/Fort 
Monmouth/1/1947 (which possesses R133), A/Denver/1/1957 (which possesses a 133 deletion), 
or A/Brisbane/59/2007 (which possesses a 133 deletion) were not dominated against the HA 
epitope involving K133 (Fig. 3.5A,B,D).  Differences in K133-specificity were statistically 
significant between the different pre-exposed groups (Fisher’s exact test p-value = 0.003 
comparing HAI titers of sera isolated from A/Texas/36/1991 pre-exposed animals to HAI titers of 
sera isolated from animals pre-exposed with other sH1N1 viruses).  Sera isolated from ferrets 
infected with only sH1N1 strains (and not pH1N1) did not react with pH1N1 or the pH1N1 mutant 
viruses.   
Unlike sera obtained from ferrets infected with pH1N1 virus only (Fig. 3.2), most sera 
samples obtained from ferrets sequentially infected with sH1N1 and pH1N1 strains did not mount 
a dominant response to the Sa antigenic site of HA (Fig. 3.5).  Notably, 0 of 3 animals 
sequentially infected with A/Texas/36/1991 and pH1N1 virus mounted responses that were 
dominated against the Sa antigenic site (Fig. 3.5C). 
To determine if sequential influenza infections induce antibodies that are capable of 
reacting to conserved epitopes on antigenically distinct influenza strains, we completed additional 
HAI assays using 2 different A/Puerto Rico/8/1934 sH1N1 strains (Table 3.4), which were 
originally isolated in 1934.  The HA of the A/Puerto Rico/8/1934-Mt. Sinai strain and the HA of the 
A/Puerto Rico/8/1934-Cambridge strain share ~98% amino acid homology with each other, but 
notably, the ‘Cambridge’ HA possesses K133 and the ‘Mt. Sinai’ HA has a deletion at this amino 
acid 32.  The HAs of the 1934 sH1N1 strains share poor homology to the HA of the pH1N1 strain 
(between 82-83% amino acid homology).  Consistent with this, sera obtained from ferrets infected 
with only pH1N1 virus did not react to either 1934 strain (Table 3.4).  Sera obtained from ferrets 
infected with only A/Denver/1/1957 reacted weakly with both 1934 strains (HAI titers 80-160), but 
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antibody titers were not boosted greatly following subsequent infection with pH1N1 virus (HAI 
titers 120-160).  Sera obtained from ferrets infected with A/Fort Monmouth/1/1947 or 
A/Brisbane/59/2007 did not react to either 1934 strain, even after a subsequent pH1N1 infection.  
Sera obtained from ferrets infected with only the A/Texas/36/1991 strain reacted weakly to the 
1934 strain possessing K133 (HAI titer 60), however these antibody titers were dramatically 
boosted following subsequent infection with pH1N1 virus (HAI titer 5120).  Consistent with the 
hypothesis that sequential infection with A/Texas/36/1991 and pH1N1 induces an antibody 
response that is dominated against an HA epitope involving K133, sera from animals sequentially 
infected with these viruses did not react to the 1934 virus with a 133 deletion (HAI titer <40).   
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Discussion 
Taken together, these data suggest that the specificity of pH1N1 antibody responses can 
be shifted to conserved epitopes in individuals that are pre-exposed to sH1N1 strains.  Previous 
studies have demonstrated that the Sa antigenic site of pH1N1 viruses is similar to the Sa 
antigenic site of some sH1N1 viruses that circulated before 1957 89,119,134,135.  H1N1 viruses did 
not circulate in humans between 1957-1977, and most H1N1 strains that circulated after 1977 
have an additional glycosylation site that shields the Sa antigenic site 135.  The addition of this 
glycosylation site in more recently circulating sH1N1 strains offers an explanation of why younger 
individuals were more susceptible compared to their elders during the 2009 pandemic.  Here, we 
have identified a very unique antibody profile in individuals born between 1983-1996.  pH1N1 
antibody responses in these individuals are not focused on the Sa antigenic site, but instead on 
an HA epitope near the receptor binding domain involving amino acid 133.   
As early as the 1960’s, it was noted that the immune system preferentially mounts 
antibody responses to previously circulating influenza strains, as opposed to new antibody 
responses that exclusively target newer viral strains 68.  Studies in the 1960’s used elegant 
absorption methods to demonstrate that antibodies induced in this manner bind to epitopes that 
are conserved between heterologous viruses 69.  We propose that cross-reactive antibodies are 
developed in this manner following infection with heterologous sH1N1 and pH1N1 viruses.  
Humans generally have high HAI titers against strains that circulated early in each individual’s 
childhood 22, indicating that most humans are infected with influenza viruses early in childhood.  
Most humans born between 1983-1996 were likely exposed to sH1N1 strains possessing K133, 
leading to the development of antibodies against the HA epitope involving K133.  We propose 
that these K133-specific antibody responses were boosted upon exposure with pH1N1 virus. 
In this manuscript, we focused on antibody responses that prevent HA binding to cell 
surfaces (HAI antibodies).  Previous studies have shown that stalk-specific antibodies are elicited 
in pH1N1-infected adult humans born between 1964-1988 77,136.  It is likely that stalk-specific 
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antibodies were also elicited in sequentially infected ferrets in our study.  Future studies will 
address if different amounts of stalk-specific antibodies are elicited in ferrets sequentially infected 
with different sH1N1 and pH1N1 viruses.  Since a large proportion of antibodies are elicited 
against the K133-HA epitope in ferrets infected with A/Texas/36/1991 and pH1N1, it is 
reasonable to speculate that a higher overall proportion of antibodies would be elicited against 
the HA stalk in ferrets infected with sH1N1 and pH1N1 viruses that do not share homology at 
amino acid 133 of HA.   
We simplified our studies by focusing on 2 amino acids.  Anti-HA antibody binding 
footprints involve several amino acids of HA, and there are most definitely other amino acids 
involved in the binding of the cross-reactive antibodies in our studies.  For example, the broadly 
neutralizing 5J8 monoclonal antibody recognizes an epitope near the receptor binding domain of 
HA involving amino acids 133, 137, and 222 132.  A recent crystal structure of the 1F1 broadly 
neutralizing monoclonal antibody with HA demonstrated that this antibody contacts many amino 
acids that influence binding with sialic acid, including amino acid 133 133.  Other broadly 
neutralizing antibodies, such as CH65, bind to the receptor binding domain of viruses that have 
the K133 deletion 137.  Interestingly, these antibodies do not bind to pH1N1 and this appears to be 
due to the presence of K133 137.  Strategically designed sequential vaccination approaches could 
elicit mixtures of broadly neutralizing antibodies with specificities such as those of 1F1 and CH65.  
This type of ‘universal vaccination’ approach would presumably protect against a large range of 
antigenically distinct influenza viruses that do and do not possess K133.   
Another implication of our studies is that ferret antisera (which is currently used for 
influenza surveillance) might not be fully representative of human population immunity.  Vaccine 
strains for H1N1, H3N2, and influenza B viruses are all selected based on HAI assays using sera 
collected from ferrets recovering from a primary infection.  Future studies should address if 
influenza viruses have evolved in response to antibodies that are elicited by sequential 
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heterologous infections, since most (if not all) evolutionary influenza studies have only utilized 
sera isolated from ferrets recovering from primary influenza infections.   
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Figure 3.1:  Modeling and electrostatics of pH1N1 HA mutants.  The structures and 
electrostatic potentials of pH1N1 HAs with G158E or K133N mutants were modeled.  Shown are 
pH1N1-WT (A) and computationally modeled pH1N1 HAs with G158E (B) or K133N (C) 
mutations.  Sialic acid is shown as a stick structure.  Surface coloring indicates electrostatic 
potential in units of kT/e where k is Boltzmann’s constant, T is temperature, and e is the 
elementary charge.   
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Figure 3.2:  pH1N1 antibody responses in previously naïve ferrets are dominated against 
Sa antigenic site of HA.  (A) HAI assays were completed using viruses possessing either wild-
type A/California/07/2009 HA, or A/California/07/2009 HA with G158E or K133N mutations.  HAI 
assays were performed with sera isolated from ferrets 14 days after infection with the 
A/California/07/2009 pH1N1 strain.  Fold escape for each mutant virus (WT HAI titer/mutant HAI 
titer) is shown here.  Each triangle represents an individual sera sample and the mean is 
indicated with a line.  HAI titers using the G158E mutant virus are lower compared to HAI titers 
using the WT virus, as determined using a paired t-test on log2 transformed data (* p=0.016).  
Data are representative of 3 independent experiments.  (B) Direct flow cytometry-based antibody 
(Ab) binding assays were completed using pooled antisera.  pH1N1-infected MDCK cells were 
incubated with ferret antisera, and antibody binding was determined after addition of a FITC anti-
ferret antibody.  Data are representative of 3 independent experiments.   
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Figure 3.3:  pH1N1 antibody responses in humans born between 1983-1996 are dominated 
against region of HA involving K133.  (A-C) HAI assays were completed using viruses 
possessing either wild-type A/California/07/2009 HA, or A/California/07/2009 HA with G158E or 
K133N mutations.  HAI assays were performed with sera isolated from humans 9-31 days after 
onset of pH1N1 symptoms.  Humans were naturally infected with pH1N1 (PCR-verified).  HAI 
titers are shown in Table S3.  Fold escape for each mutant virus (WT HAI titer/mutant HAI titer) is 
shown here.  Each triangle represents an individual sera sample and the mean is indicated with a 
line.  Individuals are separated based on year of birth.  Seven of 8 sera samples from individuals 
born between 1983-1996 had reduced titers to the K133N mutant, whereas only 2 sera samples 
from the other time periods (n=46) had reduced titers to the K133N mutant (K133-specificity of 
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sera from 1983-1996 is significantly different compared to sera from other time periods (Fisher’s 
exact test, * p-value < 0.001)).  HAI data are representative of 3 independent experiments.  (D) 
Timeline depicting the % of sH1N1 isolates possessing Lys (solid line) or a mutation/deletion 
(dotted line) at position 133 of HA based on sequences contained in the NCBI database.  In total, 
7045 sequences resulting from unique isolates were aligned using the program MUSCLE to yield 
K133 prevalence on a yearly basis.  Isolates from 1918-1957 were grouped due to low number of 
sequences from these years.  sH1N1 viruses did not circulate between 1958-1976, and this is 
indicated by a dashed vertical line. 
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Figure 3.4:  Human monoclonal antibodies specific for pH1N1 HA epitope involving amino 
acid 133 react strongly with a 1991 sH1N1 strain.  HAI assays were completed using 
monoclonal antibodies derived from pH1N1-infected humans.  HAI assays were completed using 
viruses possessing either wild-type pH1N1 HA (A/California/07/2009), pH1N1 with a G158E HA 
mutation, pH1N1 with a K133N HA mutation, or sH1N1 viruses from 1957 (A/Denver/1/1957), 
1991 (A/Texas/36/1991), or 2007 (A/Brisbane/59/2007).  Shown are minimum amounts of 
antibody required to inhibit agglutination of red blood cells in the HAI assay.  Data are 
representative of 3 independent experiments.   
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Figure 3.5:  sH1N1 pre-exposure alters the specificity of pH1N1 antibody responses in 
ferrets.  (A-D) HAI assays were completed using viruses possessing either wild-type 
A/California/07/2009 HA, or A/California/07/2009 HA with G158E or K133N mutations.  Sera were 
isolated from ferrets sequentially infected with a sH1N1 strain and then the A/California/07/2009 
pH1N1 strain.  Infections were completed 84 days apart and sera were isolated 14 days after 
infection with the pH1N1 virus.  Fold escape for each mutant virus (WT HAI titer/mutant HAI titer) 
is shown here.  Each triangle represents an individual sera sample and the mean is indicated with 
a line.  Differences in K133-specificity were statistically significant between the different pre-
exposed groups (Fisher’s exact test, * p-value = 0.003 comparing HAI titers of sera isolated from 
A/Texas/36/1991 pre-exposed animals to HAI titers of sera isolated from animals pre-exposed 
with other sH1N1 viruses).  Data are representative of 2 independent experiments. 
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Table 3.1: Rare pH1N1 isolates that escape anti-pH1N1 ferret sera.   
A/California/07/09 A/Mexico/4108/09 A/Nanchang/8008/09
A/California/07/2009 800 800 800
A/England/195/2009 800 800 800
A/Utah/42/2009 800 1200 800
A/Utah/20/2009 100 150 75
A/South Carolina/18/2009 100 150 100
A/Philippines/2810/2009 150 150 75
Virus used in HAI assay
Ferret anti-sera
 
HAI assays were completed using 6 viral isolates obtained from the CDC and 3 batches of pooled 
ferret antisera obtained from BEI resources.  Sera were isolated from ferrets infected with 3 
different A/California/07/09-like strains 19-21 days post-infection.  CDC- designated ‘non-reactors’ 
are bold. 
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Table 3.2: HA mutations in CDC identified pH1N1 ‘non-reactors’. 
Linear numbering (Met=1) 2 14 39 49 100 172 173 203 220 222 238 239 310 338
H3 numbering 26 36 87 158 159 189 206 208 224 225 296 324
A/California/07/2009 K T K L P G N A S R R D Q I
A/England/195/2009 K T K I S G N A S R R D Q V
A/Utah/42/2009 K T R L S G N A T R R G Q V
A/Utah/20/2009 E I K L S G D A S R R D H V
A/South Carolina/18/2009 K T K L S G D A T R K D Q I
A/Philippines/2810/2009 K T K L S E N V T K R D Q V  
Amino acid differences between viruses from Table S1 are shown.  Amino acid differences 
compared to A/California/07/2009 are bolded. 
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Table 3.3:  HAI titers using sera from humans infected with pH1N1.   
CAL/7/09 WT CAL/7/09 G158E CAL/7/09 K133N DEN/1/57 TX/36/91 BRIS/59/07
1 1958 240 60 240 <10 <10 20
2 1962 60 30 60 <10 640 30
3 1964 120 120 120 <10 120 30
4 1970 240 120 240 <10 <10 40
5 1972 120 120 160 <10 480 60
6 1979 3840 3840 1280 160 10240 40
7 1983 240 160 60 <10 320 <10
8 1983 240 240 40 80 1920 320
9 1984 40 40 10 <10 320 10
10 1985 40 40 10 160 2560 30
11 1986 120 120 30 40 2560 80
12 1987 80 80 20 <10 960 120
13 1992 240 320 40 <10 3840 160
14 1996 40 30 60 40 120 320
15 1997 80 60 120 <10 30 120
16 1998 20 20 40 <10 <10 <10
17 1998 30 20 60 <10 10 20
18 1998 80 80 160 <10 30 40
19 2000 160 60 120 <10 <10 <10
20 2000 80 60 120 <10 10 30
21 2000 320 480 480 <10 640 120
22 2001 240 160 240 20 120 80
23 2001 80 80 160 80 60 1920
24 2002 320 320 480 <10 <10 120
25 2003 240 120 240 <10 <10 <10
26 2003 20 15 30 <10 <10 40
27 2003 60 60 80 <10 30 60
28 2003 80 40 80 <10 40 60
29 2003 120 80 120 <10 60 120
30 2004 120 60 120 <10 <10 <10
31 2004 80 60 120 <10 <10 <10
32 2004 160 160 320 <10 20 120
33 2004 120 120 240 <10 40 120
34 2004 240 240 320 <10 80 240
35 2005 240 160 240 <10 <10 <10
36 2005 160 160 160 <10 <10 <10
37 2005 60 60 80 <10 20 480
38 2005 160 240 640 <10 60 160
39 2005 160 160 160 <10 40 120
40 2006 160 120 160 <10 <10 <10
41 2006 240 160 240 <10 <10 <10
42 2007 30 20 60 <10 <10 40
43 2007 160 240 240 <10 120 320
44 2007 960 1280 1280 <10 960 960
45 2007 480 320 480 <10 80 160
46 2008 240 60 120 <10 <10 <10
47 2008 120 60 120 <10 <10 <10
48 2008 240 240 480 <10 <10 <10
49 2008 120 120 160 <10 <10 <10
50 2008 240 120 240 <10 <10 <10
51 2008 240 120 240 <10 <10 <10
52 2008 80 240 120 <10 40 320
53 2008 240 240 320 <10 160 160
54 2009 960 480 640 <10 <10 <10
Patient no.   Birth year
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HAI assays were completed using sera isolated from humans 10-31 days after onset of pH1N1 
symptoms.  HAI assays were completed with WT pH1N1 virus (A/California/7/2009), pH1N1 
mutants, and sH1N1 viruses from 1957 (A/Denver/1/1957), 1991 (A/Texas/36/1991), and 2007 
(A/Brisbane/59/2007).  Titers using sH1N1 viruses are indicated in grey.  HAI titers that are at 
least 2-fold lower using pH1N1 mutant viruses compared to WT pH1N1 virus are indicated in red 
(for G158E mutant viruses) and green (for K133N mutant viruses). 
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Table 3.4:  Breadth of antibodies elicited by sH1N1 and pH1N1 infections. 
Infection A/Puerto Rico/8/34-Mt. Sinai A/Puerto/Rico/8/34-Cambridge
CAL/09 only <40 <40
FM/47 only <40 <40
FM/47+CAL/09 <40 <40
DEN/57 only 160 80
DEN/57+CAL/09 120 160
TX/91 only <40 60
TX/91+CAL/09 <40 5120
BRIS/07 only <40 <40
BRIS/07+CAL/09 <40 <40  
Sera were isolated from ferrets following infection with sH1N1 only, or from ferrets following 
infection with sH1N1 and pH1N1 viruses.  Sera were isolated 14 days following pH1N1 infection.  
Sera pooled from 3-4 ferrets were used in this experiment.  Shown are HAI titers using 2 A/Puerto 
Rico/8/34 strains, which were originally isolated in 1934.  The HA of the ‘Cambridge’ strain differs 
from the HA of the ‘Mt. Sinai’ strain by only 8 amino acids.  Notably, the ‘Cambridge’ HA 
possesses K133, whereas this amino acid is deleted in the ‘Mt. Sinai’ HA. 
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CHAPTER 4: Conclusion and Future Directions 
Despite major advances in many other areas of medicine, vaccination remains the prime 
strategy to combat against viral illness.  Heightened awareness of the continuous threat of new 
influenza pandemics arising from animal reservoirs or drifted strains in recent years has fueled a 
growing interest for improving the efficacy of existing seasonal influenza vaccines and for the 
development of a ‘universal’ vaccine capable for eliciting long lasting heterosubtypic protection.  
For much of the past century, we have been engaged in a continuous arms race with influenza A 
viruses.  As influenza viruses continue to acquire mutations in HA, vaccine strains are frequently 
updated in an attempt to match the antigenicity of circulating strains.  The current vaccine 
selection process is heavily reliant on antigenic cartography data generated solely based on 
traditional HAI titers against reference sera from primarily infected ferrets.  Such an approach has 
numerous limitations, and consequently there exists much room for improvement.  In this chapter, 
I will summarize how our work both highlights and provides solutions to some of these 
shortcomings in antigenic surveillance.  Additionally, I will also address how our findings advance 
the field’s understanding of the mechanisms that drive antigenic drift and offer insight for future 
vaccine strategies.   
Until the dream of a universal influenza vaccine comes to fruition, the timely and accurate 
identification of emerging circulating antigenic variants remains critical for the success of current 
influenza vaccination programs.  Current antigenic surveillance and antigenic determination 
approaches do not systematically account for the receptor binding avidities of tested strains.  
Using the Archetti-Horsfall antigenic distance metric, we demonstrated that significant shifts in 
antigenic positioning occur on antigenic maps computationally adjusted for receptor binding 
avidity (Fig. 2.1).  We then definitively demonstrated that single receptor binding altering point 
mutations can significantly alter HAI titer readouts, and consequently antigenic map positioning, 
without actually altering antibody recognition.  Due to the heavy reliance on unadjusted antigenic 
maps for vaccine strain selection, it is easy to envision how unnecessary vaccine updates can be 
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made when otherwise antigenically neutral strains appear to escape reference sera to the 
previous vaccine strain simply by acquiring mutation(s) that increase receptor binding.  Perhaps 
even more alarming, truly antigenically novel strains can be ignored if they show minimal HAI 
escape due to low receptor binding avidity.  And although strains with excessively low receptor 
binding avidities are often at a fitness disadvantage, especially in the presence of pre-existing 
immunity, compensatory secondary mutations can quickly arise, often even leading to additional 
antigenic changes 40,59,138.  Being able to accurately and quickly identify these low avidity, but truly 
antigenically distinct strains before they gain the ability to circulate broadly through additional 
compensatory mutations maybe the very key that will enable us to stay one step ahead in our 
arms race with drifted viruses.  
When defining the antigenic profiles of influenza strains, much of the field continues to 
focus only on the antigen, often neglecting the other half of the equation, the immune response.  
To truly appreciate the antigenic significance of any HA mutation, it must be interpreted in the 
context of the specificity and immunodominance of the influenza antibody response.  This is 
obvious when studying mAbs.  Two viruses that differ by a single amino acid mutation in only one 
of the antigenic sites will appear completely antigenically distinct to mAbs specific for that site.  
However the same viruses will be indistinguishable from each another when compared using 
mAbs specific for epitopes not involving the point mutation.  In the present studies, we 
demonstrated the impact that varying antibody repertoire specificity can have on antigenic 
determination from two distinct perspectives.  In chapter 2, we found that a single N145K 
mutation significantly altered the immunodominance of the anti-HA antibody response to 
A/Nanchang/933/1995, resulting in an asymmetric antigenic change.  In our ferret model, the vast 
majority of Abs elicited by the N145 variant virus recognized both the N145 and the K145 viruses 
equally.  In contrast, a large portion of antibodies elicited by the K145 variant failed to recognize 
the N145 virus, suggesting a shift in the immunodominance of the anti-HA antibody response to 
an epitope involving residue 145.  Although these findings offer a small window of insight, the 
antigenic determinants of immunodominance in B cell responses remain largely unknown.  Future 
64	  
	  
studies specifically designed to define the inherent characteristics of antigens that contribute to 
epitope immunodominance would greatly advance the development of designer vaccine antigens 
capable of eliciting very targeted antibody responses.   
In chapter 3, we demonstrated that in addition to the inherent antigenic properties of the 
eliciting antigen, the specificity of the anti-HA antibody response is also heavily influenced by the 
immune history of the host. Against pH1N1, the primary antibody response in both previously 
naïve ferrets and many pediatric patients lacking detectable HAI titers against sH1N1 strains is 
dominated against epitopes involving residues 156-160 of the Sa antigenic site 122,139 (Table 3.1 
and Table 3.2).  Accordingly, the G158E variant of pH1N1 virus showed an 8 fold decrease in HAI 
titer compared to the WT virus while the K133N variant appeared antigenically neutral when 
analyzed using sera from ferrets only infected with pH1N1 (Fig. 3.2A).  However, the antigenic 
profiles of these variants appeared drastically different when analyzed using sera from humans 
with pre-exposure to sH1N1s.  In fact, the G158E variant failed to escape any human sera set 
with sH1N1 pre-exposure history, whereas the K133N variant showed significantly decreased HAI 
titers compared to the WT pH1N1 against sera sets from humans born between 1983 and 1996 
(Table 3.3, Fig. 3.3).  Importantly, these observed variations in the specificity of the human anti-
pH1N1 antibody response correlated highly with childhood exposures to sH1N1s that shared 
homology with the pH1N1 virus in an epitope involving residue K133 (Fig. 3.3).  Furthermore, we 
were able to experimentally induce an anti-pH1N1 antibody response dominated against the 
K133 epitope in ferrets pre-exposed to a sH1N1 that possessed K133 (Fig. 3.5C).  Just as 
remarkably, this specificity was not observed with other control groups with pre-exposure to 
sH1N1 strains that lacked K133 (Fig. 3.5A, B, and D).   
Despite the mounting evidence suggesting that the nature of the anti-influenza antibody 
response is heavily influenced by immune history, sera generated in previously naïve ferrets are 
still considered as the gold standard for antigenic determination of influenza strains, for both 
surveillance and basic science studies.  While ferrets should continue to serve as the animal 
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model of choice for influenza research, future studies should consider the use of sequentially 
infected ferrets to more closely replicate the immune history seen in human patients.  Along 
similar lines, wider utilization of human serology and adoption of recent technological 
advancements such as the rapid cloning of influenza specific human mAbs will provide a much 
more clinically relevant perspective of influenza antigenic drift and the corresponding human anti-
influenza antibody response.   
In order to maximize vaccine effectiveness within the framework of the existing influenza 
vaccination strategy, we must improve our ability to predict the antigenic characteristic of future 
circulating strains and our ability to predict the specificities of Ab responses that will be elicited by 
our vaccine strains of choice.  The results presented here demonstrate that accounting for 
variations in viral receptor binding avidity and immune history will lead to improvements in each of 
these areas. However, even with perfectly chosen seed strains, the current seasonal influenza 
vaccine must still be given on a yearly basis and will be unlikely to provide protection against 
future pandemics caused by strains with novel HAs.  The 2009 pandemic and increased 
documentation of human infection by highly pathogenic avian strains in recent years have 
highlighted the need for the development of a ‘universal influenza vaccine’ capable of providing 
long-term protection against both drifted strains as well as future novel pandemic candidate 
strains.   
Our studies here along with those by other groups in recent years clearly demonstrate 
that the human immune system is capable of producing broadly cross-reactive neutralizing Abs 
against influenza 77,140-143.  Furthermore, nearly all broadly neutralizing immunoglobulin genes 
isolated from humans have been found to contain many somatic mutations and recognize older 
circulating strains with high affinity 77,78,143,144, suggesting that they were likely elicited by 
sequential exposure to different influenza strains.  However, in order to reliably replicate these 
Abs in human patients through vaccination, we must be able to differentiate the types of 
sequential exposure that leads to original antigenic sin like responses versus ones that result in 
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the production of broadly neutralizing antibodies.  An underappreciated aspect of the anti-
influenza antibody response in humans is that most of the antibodies elicited by vaccination or 
infection, including the majority of cross-reactive binding antibodies, are in fact non-neutralizing 
77,141,145.  Considering that the neutralizing epitopes of the defined antigenic sites in HA1 are likely 
the first to mutate among varying strains while non-neutralizing epitopes are under considerably 
less selective pressure to change, it is logical that an increased proportion of non-neutralizing Abs 
is typically seen in the recalled response to moderately drifted strains.  However, a different, 
possibly exploitable scenario can arise with sequential exposure to dramatically different HAs. 
The 2009 pH1N1 presented us a unique opportunity to investigate the effect of exposure to a 
distinctly novel strain on the antibody repertoire of human subjects.  With 20% variation in all HA 
residues and nearly 30% variation in HA1 residues between recent sH1N1 strains and the new 
pH1N1s, there are diminishingly few conserved epitopes, even among the non-neutralizing 
epitopes.  Despite this, several regions, including the receptor binding pocket and the fusion 
mediating stem structures, remain conserved between sH1N1s and pH1N1 due to functional 
structural limitations.  In this fortuitous experiment of nature, the tiny fraction of memory B cells 
from previous sH1N1 repertoires that were cross-reactive against these highly conserved 
epitopes were likely recalled and stimulated to further somatically mutate and expand following 
pH1N1 exposur4e.  Future experiments are needed to define the degree and characteristics of 
antigenic variation that favor the elicitation of broadly cross-protective recall responses versus 
more original antigenic sin like recall responses.  Perhaps prime/boost approaches with highly 
divergent strains can enrich for responses specific for the broadly conserved functional epitopes 
on HA while minimizing responses to antigenically variable epitopes and non-neutralizing 
epitopes.  
In conclusion, the studies presented here demonstrate that the current approach to 
influenza antigenic determination and vaccine strain selection can be greatly improved by 
accounting for receptor binding avidity and immune history.  However, even with these and other 
optimizations, seasonal influenza vaccines will continue to be limited in the breadth of the 
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protection it can offer in the face of an ever adapting target.  Moving forward, a reinvention of the 
influenza vaccine is needed to focus the immune response toward highly conserved functional 
epitopes in the context of variable pre-existing antibody repertoires.  However, through all this we 
must keep another history lesson in mind: influenza has always evolved in the face of selective 
pressure; could we simply end up pressing the reset button rather than the off button by shifting 
the immune response toward regions previously under minimal selective pressure?  
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